New developments in multitargeted therapy for patients with solid tumours

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Molecularly targeted anticancer therapies are rationally designed to interact with specific proteins involved in tumor development and progression.
• These targeted agents represent a significant advancement over traditional chemotherapy.

Purpose of the Study:

• To review the rationale and clinical data (Phase II/III) for approved and emerging multitargeted agents in solid tumor treatment.
• To discuss future challenges and strategies for optimizing the use of these agents.

Main Methods:

• Review of published Phase I, II, and III clinical trial data for approved and investigational multitargeted agents.
• Analysis of drug mechanisms of action and clinical efficacy in various solid tumor types.

Main Results:

• Approved agents like imatinib, sunitinib, sorafenib, and dasatinib have shown efficacy in licensed indications and promise in other tumor types.
• Emerging multitargeted agents demonstrate broad-spectrum activity in early-phase trials, though clinical relevance requires further validation.

Conclusions:

• Multitargeted agents have advanced cancer treatment, with approved drugs showing significant clinical benefits.
• Future efforts should focus on personalized medicine approaches, including patient selection, optimized dosing, and combination strategies to enhance therapeutic outcomes.